NSD2Nuclear Set Domain-Containing 2
References in periodicals archive ?
com)-- Ho Man Chan at Novartis will give a presentation on “Global Chromatin Profiling Leads to the Identification of NSD2 Mutations in Pediatric Acute Lymphoblastic Leukemia” at the 5th Cancer Targets & Therapeutics Conference to be held on July 7-8, 2014, in Boston, MA.
These findings identify NSD2 as a potential therapeutic target for Pediatric Acute Lymphoblastic Leukemia (ALL) and provide a general framework for the functional annotation of cancer epigenomes.